Dear Colleagues at #ASCO25 with an exciting day today in GU Oncology We invite you to read our paper. Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇 . The 2024 Advanced Prostate Cancer Consensus Conference

RT @mirrorsmed: ctDNA Detection in Cancer: A Comprehensive Overview of Current Detection Methods and Prospects. Re….

Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Meta-analysis of 19 observational studies involving up to 118,830 patients with clinically localized #ProstateCancer found that treatment with

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant #ProstateCancer. The final analysis of the

RT @OncoAlert: The OncoAlert WEEKLY RoundUp 🚨.Covering the TOP of the week July 11-17, 2025 . 👉REGISTER at OR ht….

RT @OncoAlert: Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survi….

RT @nataliagandur: 💫🌟🌍 Join the global conversation on advanced #ProstateCancer!.@APCCC_Lugano @Silke_Gillessen @AOmlin.📅 Save the date: #A….

Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair–deficient Metastatic Castration-resistant Prostate Cancer. This international retrospective study evaluated the effectiveness of anti-PD-(L)1 immune checkpoint inhibitors in 93

RT @APCCC_Lugano: Identifying cribriform and intraductal histology on magnetic resonance imaging-assisted biopsy for patients with intermed….

RT @APCCC_Lugano: Ejaculation Frequency and Risk of #ProstateCancer Updated Results with an Additional Decade of Follow-up. .

An integrated proteomic portrait of prostate cancer progression. This study uses proteomic profiling of patient-derived xenograft models to uncover key molecular changes driving #ProstateCancer progression, particularly under androgen receptor (AR)

RT @mirrorsmed: Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management an….

RT @APCCC_Lugano: A warm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 👉REGISTER HERE: .

Long-Term Outcomes After Guideline-Recommended Treatment of Men With Prostate Cancer. In a nationwide study of over 62,000 men with nonmetastatic #ProstateCancer in Sweden🇸🇪, researchers assessed long-term mortality outcomes in patients treated according

Asymptomatic Bladder Stones Exacerbate Acute Genitourinary Adverse Events During Radiation Therapy for #ProstateCancer : Insights From Two Case Reports. Teaching case report describes two prostate cancer patients with asymptomatic bladder stones who

RT @OncoAlert: Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of….

BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways. This study identifies BCL2 as a key mediator in the early development of resistance to androgen-deprivation therapy

A warm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 👉REGISTER HERE: In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and

Identifying cribriform and intraductal histology on magnetic resonance imaging-assisted biopsy for patients with intermediate-grade prostate cancer. This retrospective cohort study assessed the accuracy of MRI-assisted biopsy in detecting aggressive

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol. In the STAMPEDE phase 3 trial, researchers evaluated whether adding metformin to standard of care